论文部分内容阅读
[目的]观察柔肝健脾活血利胆法联合熊去氧胆酸(UDCA)治疗原发性胆汁性肝硬化(PBC)的临床疗效及对生化指标的影响。[方法]33例PBC患者分为对照组16例和治疗组17例,分别予以UDCA和柔肝健脾活血利胆法联合UDCA治疗,观察临床疗效、分期和生化指标的关系及指标的改善情况。[结果]①2组治疗前后临床症状体征均有不同程度的改善,治疗组缓解症状较对照组更明显(P<0.05,<0.01);②PBC早、中、晚期患者结果比较,总胆红素(TBil)渐进式上升,晚期患者丙氨酸氨基转移酶(ALT)显著下降,天冬氨酸转氨酶(AST)反而有所上升,ALT与TBil呈酶-胆分离现象,碱性磷酸酶(ALP)、γ-谷氨酰转移酶(GGT)在早期明显升高,晚期显著下降,血清清蛋白呈下降趋势;③治疗后2组患者生化指标均有所改善,而治疗组在改善血清TBil、GGT更加显著(P<0.01)。[结论]柔肝健脾活血利胆法联合UDCA治疗PBC可以明显改善患者的临床症状、体征,提高治愈率及有效率,从而提高患者的生活质量,可望减少肝移植的机率。
[Objective] To observe the clinical efficacy of Rougan Jianpi Huoxue Danxiong combined with ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis (PBC) and its effect on biochemical indexes. [Method] The 33 PBC patients were divided into control group (n = 16) and treatment group (n = 17). The patients were treated with UDCA and Rougan Jianpi Huoxue Dan GTI in combination with UDCA. The clinical efficacy, staging and biochemical indexes and the improvement of indexes were observed . [Results] The clinical symptoms and signs of the two groups improved to some extent before and after treatment, and the relieving symptoms in the treatment group were more obvious than those in the control group (P <0.05, <0.01). ②Comparison of the results of early, (ALT) and ALT (TBil) increased progressively. The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) , GGT increased significantly in the early stage and decreased significantly in the late stage, while serum albumin decreased. (3) After treatment, the biochemical indexes of the two groups were improved, while the treatment group had no significant difference in improving the serum TBil, GGT More significant (P <0.01). [Conclusion] Rougan Jianpi Huoxue Gallbladder combined with UDCA can significantly improve the clinical symptoms and signs of patients and improve the cure rate and efficiency so as to improve the quality of life of patients and reduce the probability of liver transplantation.